---
title: "Kepler Capital  Sticks to Their Buy Rating for Howden Joinery (HWDN)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284683289.md"
description: "Kepler Capital has reaffirmed its Buy rating for Howden Joinery (HWDN) with a price target of £1,100.00, while the shares closed at £799.00. Analyst Alexander Craeymeersch is ranked #6858 among 12,163 analysts. The consensus rating for Howden Joinery is Strong Buy, with a target of £998.50, indicating a 24.97% upside. Barclays also maintains a Buy rating with a £9.80 price target."
datetime: "2026-04-30T02:55:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284683289.md)
  - [en](https://longbridge.com/en/news/284683289.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284683289.md)
---

# Kepler Capital  Sticks to Their Buy Rating for Howden Joinery (HWDN)

In a report released on April 28, Alexander Craeymeersch from Kepler Capital maintained a Buy rating on Howden Joinery, with a price target of p1,100.00. The company’s shares closed yesterday at p799.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Craeymeersch is ranked #6858 out of 12163 analysts.

Howden Joinery has an analyst consensus of Strong Buy, with a price target consensus of p998.50, representing a 24.97% upside. In a report released yesterday, Barclays also maintained a Buy rating on the stock with a £9.80 price target.

### Related Stocks

- [HWDN.UK](https://longbridge.com/en/quote/HWDN.UK.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)

## Related News & Research

- [Barclays Sticks to Its Buy Rating for Howden Joinery (HWDN)](https://longbridge.com/en/news/284516569.md)
- [Insider Buying: Howden Joinery Group (LON:HWDN) Insider Acquires 18 Shares of Stock](https://longbridge.com/en/news/279371023.md)
- [Earnings Beat: Deepak Nitrite Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models](https://longbridge.com/en/news/286980047.md)
- [Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4](https://longbridge.com/en/news/286958909.md)
- [LifeSci Capital Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)](https://longbridge.com/en/news/286679129.md)